1-BOC-4-(4-氨基苯基)哌啶 | 170011-57-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-BOC-4-(4-氨基苯基)哌啶
• 中文别名: 1-N-BOC-4-(4-氨基苯基)哌啶；4-P-氨基苯基-1-BOC-哌啶；4-(4-氨基苯基)哌啶-1-甲酸叔丁酯；1-N-BOC-4(4-氨基-苯基)-哌啶；1-N-Boc-4-(4-氨基苯基)哌啶
• 英文名称: tert-butyl 4-(4-aminophenyl)piperidin-1-carboxylate
• 英文别名: tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate；1-Boc-4-(4-aminophenyl)piperidine；4-(4-aminophenyl)-piperidine-1-carboxylic acid tert-butyl ester；tert-butyl 4-(4-aminophenyl)-1-piperidinecarboxylate
• CAS: 170011-57-1
• 化学式: C₁₆H₂₄N₂O₂
• 分子量: 276.379
• InChiKey: YRLQFRXDWBFGMK-UHFFFAOYSA-N

物化性质

• 熔点：
  119 °C
• 沸点：
  412.7±45.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(4-Amino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
Synonyms: 1-Boc-4-(4-Aminophenyl)piperidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(4-Amino-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
CAS number: 170011-57-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H24N2O2
Molecular weight: 276.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

应用

1-BOC-4-(4-氨基苯基)哌啶是一种有机中间体，可通过三步反应由1-溴-4-硝基苯和4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-5,6-二氢吡啶-1(2H)-羧酸叔丁酯制备得到。

合成化合物 18.2

将4-(哌啶-4-基)苯胺盐酸盐（950mg，4.47mmol）和1,3-二氢-2-苯并呋喃-1,3-二酮（667.2mg，4.50mmol）溶解于乙酸（100mL），加热至回流后持续3小时。将所得混合物在真空下浓缩，得到白色固体状的18.2（1.49g，产率97%）。

合成化合物 18.3

将18.2（1.49g，4.33mmol）、4-二甲氨基吡啶（109mg，0.89mmol）、三乙胺（1.805g，17.84mmol）和二碳酸二-叔丁酯（1.462g，6.70mmol）溶解于二氯甲烷（100mL），在氮气保护下，在室温搅拌3小时。将所得混合物用H₂O洗涤，并用DCM萃取。合并有机层，经1MHCl和盐水洗涤后，用无水硫酸钠干燥。真空浓缩后，残余物通过硅胶色谱（EtOAc/PE, 1:30到1:10）纯化，得到白色固体状的18.3（1.44g，产率82%）。

合成化合物 18.4

在250mL圆底烧瓶中，将18.3（1.433g，3.53mmol）、NH₂NH₂·H₂O（1.84g，36.71mmol）溶解于80mL乙醇，在油浴温度下搅拌至50℃，持续4小时。固体过滤后，滤液在真空下浓缩，并用硅胶柱（乙酸乙酯/石油醚, 1:2）纯化，得到白色固体状的所需1-BOC-4-(4-氨基苯基)哌啶（446mg，产率46%）。

反应信息

• 作为反应物：
  描述：

  1-BOC-4-(4-氨基苯基)哌啶 在 对甲苯磺酸 、 potassium iodide 、 sodium nitrite 作用下， 以 乙腈 、 水 为溶剂， 反应 2.17h， 以78.1%的产率得到tert-butyl 4-(4-iodophenyl)piperidine-1-carboxylate
  参考文献：
  名称：

  作为新型P2Y 14受体拮抗剂的3-酰胺苯甲酸衍生物的设计，合成和抗炎性评估

  摘要：

  P2Y 14受体（P2Y 14 R）在调节炎症过程中起着关键作用，但是已经报道了很少种类的拮抗剂。一系列3-酰胺苯甲酸衍生物被确定为新型和有效的P2Y 14 R拮抗剂。最有效的拮抗剂16c表现出与 PPTN相当的活性（IC 50 = 1.77 nM），PPTN是最有效的P2Y 14 R拮抗剂。化合物16c在大鼠和人微粒体中显示出显着改善的水溶性和出色的代谢稳定性。16c抗炎作用的研究通过流式细胞仪，Western Blot和免疫荧光标记技术在MSU处理的THP-1细胞中进行了免疫印迹实验，结果表明16c可能是进一步研究的有希望的候选者。

  DOI：

  10.1016/j.ejmech.2019.111564
• 作为产物：
  描述：

  4-氨基苯硼酸频哪醇酯 在 palladium 10% on activated carbon 、 氢气 、 sodium carbonate 作用下， 以 甲醇 、 乙醇 、 水 、 甲苯 为溶剂， 80.0 ℃ 、137.9 kPa 条件下， 反应 4.0h， 生成 1-BOC-4-(4-氨基苯基)哌啶
  参考文献：
  名称：

  WO2020006075A5

  摘要：

  公开号：

  WO2020006075A5

文献信息

• [EN] PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS<br/>[FR] PYRROLOTRIAZINES EN TANT QU'INHIBITEURS D'ALK ET DE JAK2
  申请人：CEPHALON INC

  公开号：WO2010071885A1

  公开（公告）日：2010-06-24

  The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.

  本发明提供了一种式（I）的化合物或其盐形式，其中Q1、Q2、Q3和Q4如本文所定义。式（I）的化合物具有ALK和/或JAK2抑制活性，并可用于治疗增殖性疾病。
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011076678A1

  公开（公告）日：2011-06-30

  The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2C1)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH2NH-, -CHR''-, -(CHR'')q-O-, -O-(CHR'')q- or -(CH2)2-; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式I的化合物，其中R是氢或较低的烷基；R1是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基基团可选择地被较低的烷基，羟基，卤素或-(CH2)p-芳基取代；n为0、1或2；o为0或1；p为0、1或2；R2为CF3，环烷基，可选择地被较低的烷氧基或卤素取代，或为茚-2-基，或为杂环烷基，可选择地被杂芳基取代，或为芳基或杂芳基，其中芳香环可选择地被来自较低的烷基，卤素，杂芳基，羟基，CF3，OCF3，OCH2CF3，OCH2-环烷基，OCH2C(CH2OH)(CH2C1)(CH3)，S-较低的烷基，较低的烷氧基，CH2-较低的烷氧基，较低的炔基或氰基，或-C(O)-苯基，-O-苯基，-O-CH2-苯基，苯基或-CH2-苯基选择的一个或两个取代基取代，其中苯环可选择地被卤素，-C(O)-较低的烷基，-C(O)OH或-C(O)O-较低的烷基取代，或芳香环可选择地被杂环烷基，OCH2-氧杂环戊烷-3-基或O-四氢吡喃-4-基，可选择地被较低的烷基取代；X为键，-NR'-，-CH2NH-，-CHR''-，-(CHR'')q-O-，-O-(CHR'')q-或-(CH2)2-；Y为键或-CH2-；R'为氢或较低的烷基，R''为氢，较低的烷基，CF3，较低的烷氧基，q为0、1、2或3；或其药学上适宜的酸盐。现已发现，该式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症，焦虑症，躁郁症，注意力缺陷多动障碍（ADHD），与压力有关的疾病，如精神分裂症，帕金森病等神经疾病，阿尔茨海默病等神经退行性疾病，癫痫，偏头痛，高血压，物质滥用和代谢性疾病，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收异常，体温稳态异常，睡眠和昼夜节律异常，以及心血管疾病。
• 咪唑酮类衍生物、其药物组合物和用途
  申请人：北京富龙康泰生物技术有限公司

  公开号：CN104411706B

  公开（公告）日：2016-11-16

  本申请涉及咪唑酮类化合物、其药学可接受的盐、溶剂化物、多晶形物或前药，还涉及包含上述物质的药物组合物和用于预防和治疗蛋白激酶相关性疾病如癌症、代谢疾病、心血管疾病等的用途。
• SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT)
  作者：Michael L. Curtin、H. Robin Heyman、Richard F. Clark、Bryan K. Sorensen、George A. Doherty、T. Matthew Hansen、Robin R. Frey、Kathy A. Sarris、Ana L. Aguirre、Anurupa Shrestha、Noah Tu、Kevin Woller、Marina A. Pliushchev、Ramzi F. Sweis、Min Cheng、Julie L. Wilsbacher、Peter J. Kovar、Jun Guo、Dong Cheng、Kenton L. Longenecker、Diana Raich、Alla V. Korepanova、Nirupama B. Soni、Mikkel A. Algire、Paul L. Richardson、Violeta L. Marin、Ilaria Badagnani、Anil Vasudevan、F. Greg Buchanan、David Maag、Gary G. Chiang、Chris Tse、Michael R. Michaelides

  DOI：10.1016/j.bmcl.2017.06.018

  日期：2017.8

  disclose SAR studies that led to a series of isoindoline ureas which we recently reported were first-in-class, non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. Modification of the isoindoline and/or the terminal functionality of screening hit 5 provided inhibitors such as 52 and 58 with nanomolar antiproliferative activity and preclinical pharmacokinetics properties which enabled potent

  本文中，我们披露了导致一系列异二氢吲哚脲的SAR研究，最近我们报道它们是一流的，非底物烟酰胺磷酸核糖基转移酶（NAMPT）抑制剂。异吲哚啉的修饰和/或第5次筛选的最终功能为抑制剂（例如52和58）提供了纳摩尔的抗增殖活性和临床前药代动力学特性，在小鼠异种移植模型中口服给药时具有强大的抗肿瘤活性。讨论了结合在NAMPT活性位点上的两种抑制剂的X射线晶体结构。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06727264B1

  公开（公告）日：2004-04-27

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therepeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  这项发明涉及对黑素集中激素-1（MCH1）受体具有选择性的拮抗剂化合物。发明提供了一种药物组合物，包括治疗有效量的本发明化合物和药用可接受载体。本发明还提供了一种通过结合本发明的治疗有效量的化合物和药用可接受载体来制造的药物组合物。本发明进一步提供了一种制造药物组合物的方法，包括结合治疗有效量的本发明化合物和药用可接受载体。